Fights Aging and Increases Longevity

Metformin also has anti-aging benefits. According to studies, it can block or diminish various fundamental factors that accelerate the aging process:
1. Metformin has been shown to slow the process of aging and prevent age-related diseases by protecting against DNA damage, poor mitochondrial function, and chronic inflammation. [132-136]
2. Metformin has also been shown to increase the cellular production of mTOR and AMPK, which are longevity-promoting signaling molecules. [137-142]
3. Animal studies have shown that metformin can increase lifespan by 20%. [143-144]
4. A study found that diabetics taking metformin lived 15% longer than healthy non-diabetic individuals. [145]
5. In different mouse breeds, long-term treatment with metformin extended lifespan. [146]
6. In the United Kingdom Prospective Diabetes Study (UKPDS), metformin therapy increased life expectancy by reducing the risk of cardiovascular disease, cancer incidence, and overall mortality of diabetic patients. [147-148]
7. Studies found that metformin can reduce the levels of reactive oxygen species (ROS), which are the major cause of aging. [149-153]
8. A study found that metformin combats the effects of aging by suppressing inflammatory response via inhibition of nuclear factor κB (NFκB). [154-155]
9. A cell study found that metformin exerts its anti-aging effect by preventing cellular senescence (irreversible cell cycle arrest). [156-157]
10. In several rodent strains, adding metformin to the diet resulted in a significant increase in lifespan (14-40%). [158-161]
11. In a model of Huntington’s disease, metformin extended lifespan by 20%. [162]
12. In diabetic and cardiovascular disease patients, metformin increased rates of survival. [163-164]
13. In older adults with type 2 diabetes, metformin administration may help promote longevity by preventing frailty. [165]
14. Cell studies have shown that metformin may help combat internal aging by reducing neuronal injury and improving oxygen/glucose delivery to neurons. [166-169]